Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.

Autor:	Elhusein AM; Nursing department, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia., Fadlalmola HA; Nursing College, Taibah University, Saudi Arabia., Abedelwahed HH; Nursing College, Jazan University, Jazan, Saudi Arabia., Elshaikh AA; Nursing College, Jazan University, Jazan, Saudi Arabia., Banaga AE; Nursing College, Jazan University, Jazan, Saudi Arabia., Alrahman MHF; Nursing College, Jazan University, Jazan, Saudi Arabia., Abdelgadim NH; Nursing College, Jazan University, Jazan, Saudi Arabia., Mohammed IH; Nursing College, Jazan University, Jazan, Saudi Arabia., Abdalla AAA; Nursing College, Jazan University, Jazan, Saudi Arabia., Abdalla FAM; Nursing College, Jazan University, Jazan, Saudi Arabia., Abd Allah EM; College of Public Health, Jazan University, Saudi Arabia., Abbas NI; Nursing Department, College of Applied Medical Science, University of Hafr Al Batin, Saudi Arabia., Alhujaili AD; Nursing College, Taibah University, Saudi Arabia., Almkiy EA; Department of Nursing, Faculty of Applied Medical Sciences Buraydah College, Kingdom of Saudi Arabia., Idress EA; Nursing department, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia., Awadalkareem EM; Department of Nursing, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Saudi Arabia., Abdeldafie SY; Nursing Department, College of Applied Medical Science, University of Hafr Al Batin, Saudi Arabia., Balusamy P; Nursing Department, College of Applied Medical Science, University of Hafr Al Batin, Saudi Arabia., Mohamed RA; Department of medical laboratory technology- college of medical applied sciences- Jazan university, Saudi Arabia., Aloufi RSM; Nursing College, Taibah University, Saudi Arabia., Habiballa M; Al-Rayan Private College of Health Sciences and Nursing, Saudi Arabia., Abdelmalik MA; Al-Rayan Private College of Health Sciences and Nursing, Saudi Arabia., Alhejaili MM; Nursing College, Taibah University, Saudi Arabia., Ibrahim IA; Department of Nursing Practice, College of Nursing, Um Alqura University, Saudi Arabia., Masaad HK; Nursing Department, College of Applied Medical Science, University of Hafr Al Batin, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	African journal of reproductive health [Afr J Reprod Health] 2024 Mar 31; Vol. 28 (3), pp. 99-113.
DOI:	10.29063/ajrh2024/v28i3.11
Abstrakt:	Menopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality. The primary outcomes were a decrease in VMSs frequency and severity and safety outcomes at 4 and 12 weeks. Data were extracted and then analyzed using RevMan software. This meta-analysis included six trials with a total of 3291 women that compared Fezolinetant to a placebo in the treatment of menopausal VMSs. After 4 and 12 weeks of therapy, fezolinetant at 30 mg QD or 45 mg QD substantially decreased the frequency and severity of VMSs per 24 hours compared to placebo. Fezolinetant at 90 mg BID, 30 mg QD, or 45 mg QD did not show a significant difference in the rate of treatment-emergent adverse events (TEAEs), headache, and TEAEs leading to permanent discontinuation compared to placebo. Fezolinetant proves to be a successful and well-tolerated remedy for menopausal women suffering from VMSs. Notably, the 45 mg daily dosage over 12 weeks exhibited significant efficacy. Nonetheless, extensive future trials are necessary to ascertain its long-term safety, effectiveness, and relative potency compared to alternative VMS treatments like hormone therapy. Competing Interests: African Journal of Reproductive Health © 2024 (The Authors declared no conflict of interest.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu